Últimas noticias sobre Zeta Global Holdings (NYSE:ZETA) Bolsa

ZETA GLOBAL HOLDINGS CORP-A

Zeta Global Holdings

Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.

Analyst Color

Equities

Long Ideas

Market Summary

Downgrades

Price Target

Technicals

Initiation

Reiteration

Markets

Analyst Ratings

Trading Ideas

General

FRSH

TMSNY

ZETA

Descubre el análisis técnico y fundamental de Zeta Global en 2024: su impresionante crecimiento y las opiniones de los analistas.

Acciones de Zeta Global (ZETA) superan al NYSE Composite: ¿Deberías comprar, vender o mantener?

News

Short Ideas

CTSH

Zeta Global y Cognizant muestran signos de sobrecompra según el RSI. ¿Qué significa esto para los inversores?

2 acciones tecnológicas que podrían caer en el tercer trimestre

Zeta Global Holdings Corp. Class A Common Stock

Zeta Global Holdings Corp

ZetaChain - United States dollar

ZETA RES LTD by ZETA RES LTD

Zeta - United States dollar

Stock Split

LCID

Lucid Files Preliminary Proxy Statement To Initiate Plan For 1-for-10 Reverse Stock Split

WIIM

NUWE

Nuwellis shares are trading lower after the company announced it has terminated its REVERSE-HF clinical trial to prioritize resources and redirect investment.

INSE

Inspired Entertainment Expands Long-Term Partnership With William Hill To Deliver Comprehensive Upgrade To William Hill's Virtual Sports Offering Across Its UK Retail Estate

OKLO

Oklo shares are trading higher after the company completed the U.S. Nuclear Regulatory Commission's pre-application readiness assessment for Phase 1 of its combined license application for the Aurora Powerhouse.

Stifel analyst Jeffrey Stantial maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Hold and raises the price target from $81 to $92.

MCRI

Stifel Maintains Hold on Monarch Casino & Resort, Raises Price Target to $92

B. Riley Securities analyst Mike Crawford maintains TTM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) with a Buy and raises the price target from $36 to $50.

TTMI

B. Riley Securities Maintains Buy on TTM Technologies, Raises Price Target to $50

BTCT

BTC Digital Announces Transformative, Strategic Shift To Fully Embrace Ethereum As Core Asset And Operational Foundation; Closes $6M Financing Round, Adds New $1M ETH Position

Truist Securities analyst Matthew Coad maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $58 to $72.

AFRM

Truist Securities Maintains Buy on Affirm Holdings, Raises Price Target to $72

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.
Shares of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) fell sharply in pre-market trading after the company issued third-quarter <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46447307/abbott-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">adjusted EPS guidance below estimates.</a>
Abbott posted adjusted earnings of $1.26 per share, beating market estimates of $1.25 per share. The company's sales came in at $11.142 billion versus expectations of $11.068 billion.
Abbott Laboratories said it sees third-quarter adjusted EPS of $1.28 to $1.32, versus estimates of $1.34.
Abbott shares dipped 5.1% to $125.02 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares dipped 11.2% to $14.16 in pre-market trading.  Nuwellis shares jumped 131% on Wednesday after the company announced it secured a U.S. patent for an extracorporeal blood filtering machine and methods.</li>
<li>Pitanium Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTNM#NASDAQ">PTNM</a>) declined 7.3% to $12.41 in pre-market trading.</li>
<li>Jade Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) fell 7% to $8.20 in pre-market trading.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) dipped 7% to $54.37 in pre-market trading after the company announced a $500 million proposed public offering.</li>
<li>Ingredion Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) shares slipped 6.8% to $126.07 in pre-market trading.</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) declined 5.8% to $12.00 in pre-market trading.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) fell 4.8% to $2.55 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46439944/jim-cramer-takes-a-pass-on-this-money-losing-utilities-stock">Jim Cramer &#8216;Takes A Pass&#8217; On This Money-Losing Utilities Stock</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

INGR

JBIO

PTNM

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

VERI

Veritone shares are trading higher after the company announced it has achieved "awardable" status with the Department of Defense's P1 solutions marketplace.

Truist Securities analyst Barry Jonas maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Buy and raises the price target from $105 to $120.

Truist Securities Maintains Buy on Monarch Casino & Resort, Raises Price Target to $120

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

BMNR

BitMine Immersion Now Holds ~$1B Of Ethereum, Exceeding Initial $250M PIPE Proceeds By Over 300%

Government

Regulations

Oklo Completes US Nuclear Regulatory Commission's Pre-Application Readiness Assessment For Phase 1 Of Combined License Application For Aurora Powehouse

Oppenheimer analyst Chris Kotowski maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Outperform and lowers the price target from $57 to $55.

Oppenheimer Maintains Outperform on Bank of America, Lowers Price Target to $55

As the global economy navigates a post-pandemic world, investors are keenly observing evolving market dynamics, including shifts in consumer behavior <a href="https://www.benzinga.com/tech">and technological advancements.</a>
On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/07/16/final-trades-johnson-johnson-ice-and-the-ibit.html">Halftime Report Final Trades</a>,&#8221; Sarat Sethi, managing partner at DCLA, said he is sticking with Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) amid a positive <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46449538/johnson-johnson-raises-fy25-forecast-joins-rigetti-computing-unity-software-brighthouse-fina">earnings report</a>.
On Wednesday, Johnson &amp; Johnson raised its FY2025 earnings guidance. The company reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.74 billion, up 5.8% year-over-year and beating the consensus estimate of $22.85 billion.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, named iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) as his final trade.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Joseph M. Terranova, senior managing director for Virtus Investment Partners, picked Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) as his final trade.
Lending support to his choice, Piper Sandler analyst Patrick Moley maintained an Overweight rating for Intercontinental Exchange on Tuesday, raising the price target from $180 to $202.
Price Action:
<ul class="wp-block-list">
<li>Johnson &amp; Johnson shares dipped 5.5% to close at $78.86 on Tuesday.</li>
<li>iShares Bitcoin Trust ETF gained 2.5% during the session.</li>
<li>Intercontinental Exchange shares rose 0.6% to close at $180.80 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46439944/jim-cramer-takes-a-pass-on-this-money-losing-utilities-stock">Jim Cramer &#8216;Takes A Pass&#8217; On This Money-Losing Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Media

IBIT

Johnson & Johnson, Intercontinental Exchange And Bitcoin ETF On CNBC's 'Final Trades'

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $4 price target.

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target

DGXX

Digi Power X shares are trading higher after the company announced it has executed a definitive purchase order with Super Micro Computer to supply NVIDIA B200-powered systems.

Oppenheimer analyst Noah Kaye maintains Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Outperform and raises the price target from $132 to $140.

Oppenheimer Maintains Outperform on Vertiv Holdings, Raises Price Target to $140

Oppenheimer analyst Kristen Owen maintains Trimble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) with a Outperform and raises the price target from $81 to $88.

TRMB

Oppenheimer Maintains Outperform on Trimble, Raises Price Target to $88

Press Releases

March's Zeta Economic Index (ZEI) Indicates Economic Cooling as Consumer Confidence Wanes

Zeta Global to Announce First Quarter 2025 Results on May 1, 2025

Zeta Global Reports 15th Straight "Beat and Raise" Quarter

April's Zeta Economic Index Highlights Emerging Disconnect: Consumers Feel Uneasy, But Keep Spending

Cannae Holdings, Inc. Announces Executive Management Succession, Board Refreshment, and Additional Strategic Actions to Unlock Shareholder Value

Zeta Economic Index (ZEI) Shows Consumers in Holding Pattern as Stability Rises and Activity Cools

Zeta Global Unveils 'Zeta Answers,' Ushering in the Next Era of Agentic Marketing

Zeta Global Honors Co-founder and Visionary Board Member, John Sculley, on His Retirement

Comments

Zeta Global Holdings

Noticias

Últimas noticias sobre Zeta Global Holdings (NYSE:ZETA) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL